PCYN PROCYON CORP

OTC Pharmaceutical Preparations CO CIK: 0000812306
AI RATING
SELL
75% Confidence

Investment Thesis

Procyon Corp demonstrates a critical operational disconnect: excellent gross margins of 78.1% are negated by severe cost control failures, resulting in negative operating margins (-4.6%) and net losses despite 6.4% revenue growth. Deteriorating profitability (-9% net income YoY) and negative free cash flow (-125.2K) indicate unsustainable business dynamics. While the balance sheet is solid with minimal debt, the company must achieve dramatic operational efficiency improvements before cash reserves are depleted.

Strengths

  • + Exceptional gross margin of 78.1% demonstrates strong underlying product economics and pricing power
  • + Solid balance sheet with minimal leverage (0.02x debt/equity ratio) provides financial stability
  • + Strong liquidity position with 3.08x current ratio and 326.1K cash reserves provide operational runway

Risks

  • ! Persistent unprofitability at operating level (-231.7K operating income) despite substantial gross profits reveals severe cost discipline issues
  • ! Negative free cash flow of -125.2K combined with deteriorating net income (-9% YoY) indicates unsustainable cash burn trajectory
  • ! Operating expenses exceed 80% of gross profit, consuming all margin gains and requiring fundamental restructuring to achieve viability
  • ! Data freshness concern with most recent period ending June 30, 2024; absence of recent filings limits current performance visibility

Key Metrics to Watch

Financial Metrics

Revenue
5.0M
Net Income
-341.1K
EPS (Diluted)
$-0.04
Free Cash Flow
-125.2K
Total Assets
3.2M
Cash
326.1K

Profitability Ratios

Gross Margin 78.1%
Operating Margin -4.6%
Net Margin -6.8%
ROE -14.9%
ROA -10.6%
FCF Margin -2.5%

Balance Sheet & Liquidity

Current Ratio
3.08x
Quick Ratio
2.41x
Debt/Equity
0.02x
Debt/Assets
28.6%
Interest Coverage
N/A
Long-term Debt
50.7K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-14T03:09:29.492405 | Data as of: 2024-06-30 | Powered by Claude AI